Key highlights

  • Monash IVF Group (ASX:MVF) expects FY27 underlying net profit to be materially below FY26 if market activity does not improve in the second half.
  • The Australian stimulated-cycle market contracted 3.2% from Q4 FY26 to Q1 FY27.
  • Management maintained the AUD 8 million to AUD 11 million annualised pre-tax savings target.

Shares in Monash IVF Group (ASX:MVF) were down 21.52% at AUD 0.593 at 11:25 a.m. AEDT on 20 November 2026. At 12:30 p.m. AEDT, the S&P/ASX 200 was at 8,596.80 and all 11 sectors were lower. The fertility services provider released an FY27 trading update on 20 November 2026 covering cycle volumes, costs and the use of new facilities.

First-quarter cycle volumes and market share

On 20 November 2026, Monash IVF reported that the Australian stimulated-cycle market contracted 3.2% in Q1 FY27 compared with Q4 FY26. Its rolling 12-month Market Share was 19.4%, broadly in line with the position at 30 June. The company reported quarter-on-quarter gains in share across the states where it operates except South Australia, where it cited new local competition.

Management reported improved Earnings performance in October and November compared with the first quarter, reflecting higher volumes and work under its productivity program. The second-half outlook assumes that overall market activity does not improve. On that basis, Monash IVF expects FY27 underlying net profit after tax to be materially below FY26. The company did not quantify the expected full-year result.

Savings program and Facility ramp-up

Monash IVF reported higher occupancy costs, wages and insurance premiums, together with increases from some suppliers. It maintained a target of AUD 8 million to AUD 11 million in annualised pre-tax savings, though it expects the benefits to take longer than previously anticipated. Current measures include changing staffing levels, negotiating with suppliers and reviewing discretionary spending.

Brisbane operations temporarily closed for around one month in July during a facility move. Monash IVF expects the new site to reach steady operations by the end of Q2. The group also started bringing additional ultrasound capacity online alongside its Fertility North clinic, with a staged start for higher-acuity scans and procedures. The new Clayton facility remained on track to open to patients in December 2026, and the company reported that procedure volumes at Cremorne increased 22% from Q4 to Q1 after surgical activity was consolidated there.

Healthcare sector context

The health care sector was down 1.41% in the broader market. In fertility services, stimulated-cycle activity was the Volume measure highlighted by Monash IVF in its Australian trading update. The company reported month-to-month variation in cycle numbers and distinguished movement in that market from the performance of its own clinics and international business.

Risks investors are watching

Monash IVF is absorbing facility costs before volumes build at new sites. The group expects higher Depreciation and interest expense than in FY26 after Investment in capacity and an increase in debt. The timing of cost savings and utilisation of the new facilities remain variables for earnings, alongside Demand for stimulated cycles.

What to watch ahead

The half-year results are due to include a further trading update. Site milestones include the opening of Clayton to patients in December, higher utilisation in Brisbane and the phased addition of ultrasound activity. The rate of savings realised will show how the program is progressing against its annualised target.

Where FY27 trading stands

The November update puts softer first-quarter market volumes and higher costs alongside improving trading in October and November. The full-year earnings outlook remains conditional on subsequent market activity and the pace of operational changes.